{
    "ticker": "ALKS",
    "name": "Alkermes plc",
    "description": "Alkermes plc is a global biopharmaceutical company that focuses on the development of innovative medicines for the treatment of central nervous system (CNS) diseases and cancer. Headquartered in Dublin, Ireland, Alkermes has a rich history of leveraging its unique drug delivery technologies and deep scientific expertise to create treatments that address unmet medical needs. The company is particularly known for its products such as Vivitrol, a medication for the treatment of alcohol dependence and opioid dependence, and Aristada, an extended-release formulation for the treatment of schizophrenia. Alkermes is committed to advancing the science of CNS disorders and oncology through rigorous research and development efforts, with a pipeline that includes several promising candidates targeting various conditions, including depression, addiction, and cancer. The company emphasizes collaboration with the medical community and patient advocacy groups to improve patient outcomes and quality of life. With a strong focus on innovation and a patient-centric approach, Alkermes aims to be a leader in the biopharmaceutical space, dedicated to delivering transformative therapies to those in need.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "Dublin, Ireland",
    "founded": "2010",
    "website": "https://www.alkermes.com",
    "ceo": "Richard Pops",
    "social_media": {
        "twitter": "https://twitter.com/alkermes",
        "linkedin": "https://www.linkedin.com/company/alkermes/"
    },
    "investor_relations": "https://investor.alkermes.com",
    "key_executives": [
        {
            "name": "Richard Pops",
            "position": "CEO"
        },
        {
            "name": "James Frates",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "CNS Products",
            "products": [
                "Vivitrol",
                "Aristada"
            ]
        },
        {
            "category": "Oncology Products",
            "products": [
                "Merck's Keytruda (co-developed)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Alkermes plc | Innovative Biopharmaceuticals for CNS and Cancer",
        "meta_description": "Explore Alkermes plc, a biopharmaceutical company dedicated to developing innovative therapies for central nervous system diseases and cancer.",
        "keywords": [
            "Alkermes",
            "Biopharmaceuticals",
            "CNS Disorders",
            "Cancer Treatment",
            "Vivitrol",
            "Aristada"
        ]
    },
    "faq": [
        {
            "question": "What is Alkermes known for?",
            "answer": "Alkermes is known for its innovative treatments for central nervous system disorders and cancer."
        },
        {
            "question": "Who is the CEO of Alkermes?",
            "answer": "Richard Pops is the CEO of Alkermes plc."
        },
        {
            "question": "Where is Alkermes headquartered?",
            "answer": "Alkermes is headquartered in Dublin, Ireland."
        },
        {
            "question": "What are Alkermes' main products?",
            "answer": "Alkermes' main products include Vivitrol and Aristada."
        },
        {
            "question": "When was Alkermes founded?",
            "answer": "Alkermes was founded in 2010."
        }
    ],
    "competitors": [
        "REGN",
        "VRTX",
        "AMGN",
        "BIIB"
    ],
    "related_stocks": [
        "JNJ",
        "PFE",
        "ABBV",
        "GILD"
    ]
}